SINCE the folic acid analogues were introduced as antineoplastic agents in 1948 by Farber et al., a variety of dose schedules have been explored. Goldin and his colleages reported 2 methods of improving the therapeutic index of methotrexate (MTX) as measured by the prolongation of survival of CDBA hybrid mice with Leukaemia 1210. The first method consisted of administration of MTX every fourth day rather than twice daily, once daily, or every second day (Goldin, Venditti, Humphreys and Mantel, 1956 ). The superiority of this dose schedule of MTX over daily medication was confirmed for maintenance of remission in childhood leukaemia (Acute Leukaemia Group B, 1965) . The second method Please address reprint requests to Heine H. Hansen, M.D., NCI-VA Oncology Service, V.A. Hospital, 50 Irvine Street, N.W. Washington, D.C. 20422. included sequential use of MTX and leukovorin (N5-formyl tetrahydrofolic acid, citrovorum factor, folinic acid) in order to facilitate recovery of vital host cells at a time when tumour cells were presumably irreversibly damaged (Goldin, Venditti, Kline, and Mantel, 1966) .
Therefore the present study was designed to define the individual tolerance to single or widely spaced doses of MTX, as a baseline for exploration of the optimal time interval and dose ratio of MTX followed by leukovorin (Selawry, 1970) .
MATERIALS AND METHODS
Forty-nine patients with histologically confirmed diagnosis of cancer were placed under study. Eleven MTX was administered as a 1 -hour infusion in 50 per cent increments every 2 weeks until individual tolerance was reached.
individual tolerance. It can be observed that the different manifestations of toxicity are independent of the individual toxic levels with the possible exception of conjunctivitis, alopecia, nausea, and vomiting, which all occurred more than twice as frequently at higher doses.
The predominant dose limiting toxicity was leukopenia (Table I ) occurring in 40 of 49 patients (81 %). Thrombocytopenia was never the single dose limiting factor. Leukopenia was accompanied by stomatitis in 22 patients (45 %). Nine patients (19 %) had oral ulcerations as the only toxic manifestation. Dose limiting toxicity was never reached without leukopenia or stomatitis being present. The kinetics of the most common types of toxicity are summarized in Table III. TABLEIII. Oral toxicity occurred within 3 to 6 days after MTX administration. Leukopenia started at a median of 6 days, proceeded to a nadir on day 8 and recovered by day 13. In 5 patients, a second nadir of leukopenia was observed, occurring 13-20 days after exposure toMTX, always less pronounced than the first nadir. Thrombocytopenia occurred by day 9 (median), reached a nadir on day 11, and lasted until day 14. However, considerable variation in the time of onset and nadir, and the duration of depression of both cell elements was found. In some patients the fall in platelet levels was followed by " rebound " thrombocytosis before return to pretreatment levels. In 16 patients the platelet count rose to above 600,000/mm.3 and of these, 9 patients had a count above 800,000/mm.3 with a maximum count of 1,220,000/mm.3 on day 15 in 1 patient. No similar pronounced rebound was observed for leukocytes. The minimum reticulocyte count was observed from 2-7 days after MTX administration (median 5 days). Three patients died with infection in the presence of pronounced haematologic toxicity on day 7, 8, and 11, respectively, after exposure to the first dose of MTX of 120, 120, and 180 mg./m2. The nadir of the white blood count was 500, 1100, and 200/mm. , and of the platelets, 50,000, 5000, and 3000/mm. . None of these patients had demonstrable invasion of the bone marrow by tumour cells, or were exposed to extensive pretreatment radiotherapy. The ages of the patients were 65, 40, and 51 years, respectively. Less common toxic manifestations (Table II) included reversible erythrodermic rash, conjunctivitis, hepatotoxicity, diarrhea, and alopecia. The hepatic toxicity was evidenced by transient elevation of SGOT (range, 63 to 107; normal < 45 Karmen units) with a peak elevation occurring after 6 to 10 days and a return to normal within 15 to 20 days. In addition, 2 patients demonstrated hyperbilirubinemia with maximums of 6-5 mg./100 ml.
and 5-4 mg./100 ml., respectively. One of these patients who had a biopsyproven diagnosis of liver cirrhosis before treatment, but normal liver chemistries at the time of reciving a MTX dose of 120 mg./m2, died on day 16 in hepatic failure.
No biochemical abnormalities had been noted following the preceding dose of 80 mg./m2. Prediction of tolerance to MTX.-The wide spread of individual tolerance to MTX makes it desirable to define predictive factors. When the patient, with age range 26 to 75 years and median age 54, were divided into 2 groups, 1 with " low " (80 to 120 mg./m2) and 1 with " high " (180 to 900 mg./m2) tolerance to MTX, the patient's age represented the only recognizable difference between the 2 groups. Patients with high tolerance were significantly younger than patients with lower tolerance to MTX (P < 0.001). Cachexia, as defined by weight loss from onset of disease until treatment with MTX, pretreatment serum albumin levels, and pretreatment serum folate showed no correlation with the development of MTX toxicity (Table IV) . Furthermore, previous myelosuppressive treatment such as radiotherapy and chemotherapy did not appear to influence tolerance to MTX (Table V) .
Therapeutic effect.-Evaluation of antitumour effect in the 49 patients is shown in Table VI However, other phenomena more directly related to the mechanism of action of MTX might also contribute to the variability of individual drug tolerance.
An inverse correlation between toxicity from MTX and levels of intestinal folic reductase in rats and mice has been demonstrated (Werkheiser, 1961) . In addition it has been suggested by Werkheiser (1963) that differential permeability through cell membranes is responsible for the differential sensitivity of dividing cells in which the concentration of folic acid reductase is comparable. Furthermore, the initial rate of uptake of the drug as well as the capacity of the cells to retain MTX has varied among different patients (Bertino, 1963) . Additional factors for the variability of MTX tolerance in humans include drug interaction between MTX and other pharmacologic agents administered at the same time. For example, it has been shown that riboflavin competitively inhibits the carriermediated influx of MTX into the L1210 mouse leukaemia cell (Lichtenstein and Goldmann, 1970) . Recent data have also indicated that organic acids such as acetylsalycilic and para-aminohippuric acid inhibit a renal tubular mechanism of MTX excretion in humans (Liegler et al., 1969) . In addition, salicylates, as well as sulfathiazole, decrease the binding capacity of serum protein by an average of 30 % and 28 %, respectively (Leigler et al., 1969) . It has also been demonstrated in mice that antimicrobial agents such as neomycin and sulfathiazole reduce the metabolism of MTX in the intestinal tract by decreasing the intestinal flora (Zaharko, Bruckner, and Oliverio, 1969) . Further detailed controlled human pharmacologic studies are indicated for clarification of some of these problems.
The findings of subnormal levels of folic acid activity with a median value of 2* 1 ng./ml. in patients with metastatic cancer confirms previous reports (Hellmann, Iannotti, and Bertino (1965) , Magnus (1967 ), Rama Rao et al. (1965 . The lack of correlation between pretreatment serum folate and maximum tolerated dose of MTX might reflect limitations in the correlation of serum folate to the intracellular folate pool. In this regard it has been noted that levels of folic acid activity in red cells are normal in cancer patients even though serum folate is reduced (Magnus, 1967) .
The kinetics of haematologic toxicity encountered in the present study are analogous to those described by Condit and his colleagues (Condit, 1960; Condit et al., 1960 Condit et al., , 1962 who observed a different kinetic pattern for leukocytes, thrombocytes, and erythrocytes following a single large dose of MTX. Rebound thrombocytosis has also been previously noted; its origin is somewhat obscure; it has been speculated that it reflects the activity of a thrombopoietin (Ogston, Dawson, and Philip, 1968) .
The frequency of hepatic abnormalities occurring after administration of MTX is in accordance with observations by others (Gottlieb and Serpick, 1970; Hersh et al., 1966) and might be even higher than noted if studies were obtained daily after MTX. Acute hepatotoxicity of clinical importance, however, is uncommon, and was limited to hepatic coma in a patient with pre-existing biopsyproven hepatic cirrhosis. A similar case of drug related death in hepatic coma in a patient with cirrhosis has been reported by Lane (1968) . This emphasizes that MTX should be used with utmost caution in patients with pre-existing, definite impairment of hepatic function.
The high proportion of toxic manifestations observed at low single dosage of MTX, including lethal haematologic toxicity in 3 patients after administration of 120, 120, and 180 mg./m2 indicates that initial single doses of 200 mg./m2 previously reported by Condit et al. (1962) are not safe. Some of this discrepancy may be related to the infusion period of 1 hour in this study leading to more prolonged exposure of sensitive tissue to MTX in our study compared with the i.v. " push " administration used by Condit. Based on the present data, 80 mg./m2 by 1 hour infusion is the highest recommended starting dose of parenteral administration of MTX at widely spaced intervals.
It is possible that the life-threatening toxicity observed at an initial MTX dose of 120 mg./m2 and 180 mg./m2 compared with the same dose level given after exposure to a nontoxic dosage is elicited by induction of adaptive dihydrofolic reductase which might bind MTX at the subsequent exposure. Such a hypothesis is supported by studies of Bertino et al. (1962 Bertino et al. ( , 1963 indicating that both leukaemic and non-leukaemic leukocytes and erythrocytes develop high levels of dihydrofolic reductase after treatment with MTX.
The study was primarily designed for determination of host tolerance, and most of the tumours were not measurable. Against this background, it is noteworthy that objective tumour response was observed in patients with bronchogenic carcinoma, head and neck tumours, prostatic cancer, and penile cancer. This confirms the wide spectrum of tumours sensitive to MTX. It should be stressed that widely spaced doses of MTX do not appear to be optimal as a schedule for treatment of solid tumours. It stands to reason that the therapeutic index of this agent can be improved either by more frequent administration of MTX alone or followed by leukovorin " rescue " (Capizzi et al., 1970; Hryniuk and Bertino, 1969; Mitchell et al., 1968; Schwarzenberg et al., 1969) or, as suggested by Schabel (1969) , by using the cell cycle specific drug MTX in combination with a cell cycle non-specific agent such as an alkylating agent.
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